Navigation Links
For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
Date:4/29/2009

The Combination of Bapineuzumab and Donepezil Will Earn Decision Resources' Gold Standard Status for the Indication in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists identify a therapy's effect on cognitive decline as the attribute that most influences their prescribing decisions in mild to moderate Alzheimer's disease. As potential disease-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's Dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in the market.

The new report entitled Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status also finds that a therapy that prevents cognitive decline for a longer duration than donepezil for the treatment of mild to moderate Alzheimer's disease would earn a 50 percent patient share in the United States and a 45 percent patient share in Europe, according to surveyed U.S. and European neurologists.

In 2008, Decision Resources' proprietary clinical gold standard for mild to moderate Alzheimer's disease was donepezil. Based on available data and expert opinion, the combination of bapineuzumab and donepezil will earn gold standard status for the indication in 2012, following the approval of bapineuzumab in 2012.

"The bapineuzumab/donepezil combination, as a potential disease-modifying drug, may have competitive advantages in efficacy outcomes, including effect on cognitive decline," said Decision Resources Director Andrea Witt, Ph.D. "Thought leaders perceive this regimen as having the greatest potential efficacy in Alzheimer's disease and preliminary clinical trial results suggest that monoclonal antibodies such as bapineuzumab may have a greater impact than other emerging agents on all efficacy measures."

About the Report

Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Renal function and heart disease, and more
3. Environmental stress probed in cardiovascular disease, diabetes
4. Study Links Coronary Disease, Colon Cancer
5. People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter
6. To fight disease, animals, like plants, can tolerate parasites
7. Researchers Spot Link Between Heart Disease, Income
8. Children with sickle cell disease, silent strokes show some relief with blood transfusions
9. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
10. U.S. Deaths Down From Heart Disease, Stroke
11. Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
Breaking Medicine Technology: